文章：

CAR T细胞疗法在多发性骨髓瘤中：仍有更大的改进空间

CAR T-cell therapy in multiple myeloma: more room for improvement

原文发布日期：2021-04-29

DOI: 10.1038/s41408-021-00469-5

类型: Review Article

开放获取: 是

英文摘要：

The emergence of various novel therapies over the last decade has changed the therapeutic landscape for multiple myeloma. While the clinical outcomes have improved significantly, the disease remains incurable, typically in patients with relapsed and refractory disease. Chimeric antigen receptor (CAR) T-cell therapies have achieved remarkable clinical success in B-cell malignancies. This scope of research has more recently been extended to the field of myeloma. While B-cell maturation antigen (BCMA) is currently the most well-studied CAR T antigen target in this disease, many other antigens are also undergoing intensive investigations. Some studies have shown encouraging results, whereas some others have demonstrated unfavorable results due to reasons such as toxicity and lack of clinical efficacy. Herein, we provide an overview of CAR T-cell therapies in myeloma, highlighted what has been achieved over the past decade, including the latest updates from ASH 2020 and discussed some of the challenges faced. Considering the current hits and misses of CAR T therapies, we provide a comprehensive analysis on the current manufacturing technologies, and deliberate on the future of CAR T-cell domain in MM.
 

摘要翻译： 

过去十年间，各类新型疗法的出现改变了多发性骨髓瘤的治疗格局。尽管临床疗效已显著改善，但该疾病通常仍无法治愈，尤其是在复发和难治性疾病患者中。嵌合抗原受体（CAR）T细胞疗法在B细胞恶性肿瘤领域已取得显著临床成功，这一研究范畴近期已扩展至骨髓瘤领域。虽然B细胞成熟抗原（BCMA）是目前该疾病中研究最深入的CAR T细胞靶点，但许多其他抗原也正受到深入研究。部分研究显示出令人鼓舞的结果，而另一些则因毒性及缺乏临床疗效等原因呈现不理想的结果。本文综述了CAR T细胞疗法在多发性骨髓瘤中的应用，重点阐述了过去十年取得的进展（包括2020年美国血液学会年会的最新动态），并探讨了当前面临的部分挑战。基于目前CAR T疗法成败并存的现状，我们对现有生产技术进行了全面分析，并对多发性骨髓瘤CAR T细胞治疗领域的未来发展进行了展望。

原文链接：

CAR T-cell therapy in multiple myeloma: more room for improvement